# OptiTROP-Breast01 (NCT05347134)

> SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05347134
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Conditions: Triple Negative Breast Cancer
- Interventions: SKB264
- Enrollment: 254
- Primary outcome: Progression-free survival (PFS)

## Indexed commentary on OptiTROP-Breast01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 37
- Podcasts: 14
- YouTube: 10

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=optitrop-breast01-nct05347134

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05347134", "email": "<work email>"}; the inbox owner confirms by the emailed link.